TINA S MUTKA
Nursing at Chaperon Ct, Tampa, FL
License number
Florida 9377717
Issued Date
Feb 20, 2014
Effective Date
Mar 3, 2015
Expiration Date
Apr 30, 2019
Category
Health Care
Type
Registered Nurse
Address
Address
2
7815 Chaperon Ct, Tampa, FL 33637
1324 Lakeland Hills Blvd, Lakeland, FL 33805
1324 Lakeland Hills Blvd, Lakeland, FL 33805
Phone
(561) 758-6738
Personal information
See more information about TINA S MUTKA at radaris.comName
Address
Phone
507 N Broadway, Lantana, FL 33462
7815 Chaperon Ct, Tampa, FL 33637
Tampa, FL
3230 Archer Rd, Gainesville, FL 32608
307 Broadway, Lake Worth, FL 33462
Professional information
4(1H)-Quinolones Having Antimalarial Activity With Reduced Chemical Resistance
US Patent:
2013012, May 16, 2013
Filed:
Oct 26, 2012
Appl. No.:
13/661300
Inventors:
Roman Manetsch - Tampa FL, US
Richard Matthew Cross - Brandon FL, US
Dennis Edward Kyle - Lithia FL, US
Tina Susanna Mutka - Tampa FL, US
Alexis Nichole LaCrue - Temple Terrace FL, US
Jordany Richarlson Maignan - Tampa FL, US
Fabian Ernesto Saenz - Quito, EC
Richard Matthew Cross - Brandon FL, US
Dennis Edward Kyle - Lithia FL, US
Tina Susanna Mutka - Tampa FL, US
Alexis Nichole LaCrue - Temple Terrace FL, US
Jordany Richarlson Maignan - Tampa FL, US
Fabian Ernesto Saenz - Quito, EC
International Classification:
C07D 215/233, C07D 413/04, C07D 401/04, C07D 215/56
US Classification:
5142352, 514312, 546156, 546153, 544128, 544363, 51425307
Abstract:
Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of a infection in the recipient subject, or to reduce the likelihood of the onset or establishment of a infection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time.